JAN 27, 2017 11:31 AM PST

Bezlotoxumab for recurrent C. difficile infections

WRITTEN BY: Kerry Evans

Clostridium difficile often infects hospitalized patients who have undergone antibiotic therapy. These bacteria infect the gut, causing diarrhea and colitis. These infections are serious and can even be fatal.

 

Although C. difficile can be treated with antibiotics, the infection often recurs.  

 

C. difficile bacteria

 

According to study author Mark Wilcox from the University of Leeds, “about one in four patients who have been treated with antibiotics for an initial C.diff infection will go on to have a repeat infection. These repeat infections are more difficult to treat, have more severe outcomes for the patient, and are associated with more hospitalisations. It is important to treat the first episodes of C. diff infection optimally, as each recurrence increases the chance of another episode even more.”

 

With this in mind, Wilcox and colleagues conducted two phase 3 trials to determine if monoclonal antibodies against C. difficile toxins could help prevent recurrent infections. Bezlotoxumab is a monoclonal antibody against toxin B, and actoxumab is a monoclonal antibody for toxin A.

 

The studies (MODIFY I and MODIFY II) were conducted with 2,655 adults at 322 sites in 30 countries. Participants received, in addition to standard antibiotic treatment (vancomycin, metronidazole, or fidaxomicin), bezlotoxumab, actoxumab, both bezlotoxumab and actoxumab, or a placebo (saline).

 

In the MODIFY I study, infection recurred (within 12 weeks of initial cure) in 28% of participants receiving the placebo, but only in 17% of people receiving bezlotoxumab. The rates were very similar in the MODIFY II study. The effect of actoxumab and bezlotoxumab together was similar to that of bezlotoxumab alone. In addition, the rates of recurrent infection in high-risk patients were lower for the bezlotoxumab group and the combined actoxumab/bezlotoxumab groups compared to the placebo group.

 

The researchers also looked at an endpoint they termed “sustained cure,” defined as initial cure with no recurrent infection over the next 12 weeks. In pooled data from the MODIFY I and II studies, 64% of participants in the bezlotoxumab group achieved sustained cure, compared to 58% in the actoxumab/bezlotoxumab group and 54% in the placebo group.

 

Overall, bezlotoxumab lowered the risk of first post-treatment relapse by 40% compared to standard treatment alone.

 

Bezlotoxumab is approved by the FDA and will soon be available to doctors treating C. difficile infections. However, in a commentary on this study, John G. Bartlett questions whether using bezlotoxumab is really cost-effective. He notes that, while effective, bezlotoxumab may not need to become the standard of care - fidaxomicin already effectively prevents recurrent infections, and antibiotic resistance has not been an issue for treating C. difficile infections.

 

This new treatment regimen may, however, benefit high-risk patients - those older than 65, people with kidney issues, or those already on antibiotics, for example. "The studies showed that bezlotoxumab was particularly effective in those patients with risk factors for poor outcome, including older age, immunocompromise, and severe infection," says Wilcox.

 

 

Sources: NEJM article, NEJM commentary, Science Daily

 
About the Author
  • Kerry received a doctorate in microbiology from the University of Arkansas for Medical Sciences.
You May Also Like
NOV 19, 2019
Genetics & Genomics
NOV 19, 2019
Why Some Places Have More Baby Girls than Boys
Typically, there are more male babies born than females, with the global average lying at 105 boys born for every 100 girls. Although more males are born a...
NOV 19, 2019
Genetics & Genomics
NOV 19, 2019
DNA Analysis Shows How Algae Respond to a Changing Environment
While a type of algae appears to be thriving in the face of its downgraded envrionment, the story is turning out to be more complex....
NOV 19, 2019
Cell & Molecular Biology
NOV 19, 2019
A Protein Sensor That Helps a Stomach Bug Find a Good Home
A bacterial pathogen called Helicobacter pylori is known to colonize the stomach and cause ulcers....
NOV 19, 2019
Genetics & Genomics
NOV 19, 2019
Gene Mutations Link Flu Infections and Heart Trouble
Sometimes people develop life-threatening heart complications when they're infected with the flu....
NOV 19, 2019
Immunology
NOV 19, 2019
Researchers Identify Pair of "Recruiters" that Pull T Cells to the Lungs
How do CD8 T cells make it to the lungs to help in the fight against infection? Why don’t T cells remain longer in the lungs? How can science optimiz...
NOV 19, 2019
Clinical & Molecular DX
NOV 19, 2019
Meningitis and Encephalitis: Testing & Diagnosis Strategies for Effective Treatment
Meningitis is an inflammation of the membranes surrounding the brain (meninges) and spinal cord. Encephalitis, on the other hand, refers to inflammation of...
Loading Comments...